Funded Startups in Nedlands
Across the 7 most recent funded startups listed for Nedlands, the largest disclosed round is OncoRes Medical’s $19M on 2026-02-12, which is substantially l…
Across the 7 most recent funded startups listed for Nedlands, the largest disclosed round is OncoRes Medical’s $19M on 2026-02-12, which is substantially larger than the next-highest disclosed amounts (BARD1 Life Sciences at $11M on 2021-07-23 and My Mirror at $4M on 2024-12-01). The only biotech-focused entries appear in the middle of the timeline as well: 4 of 7 companies are in Biotechnology (OncoRes Medical on 2026-02-12; Argenica Therapeutics on 2023-01-20; Lixa on 2022-09-06; BARD1 Life Sciences on 2021-07-23).
Temporally, the recent cluster is sharp at the top: 3 of 7 rounds are dated in 2026 (Tali Resources $2M on 2026-05-07; Stavely Minerals $3M on 2026-04-29; OncoRes Medical $19M on 2026-02-12). Stages are mixed, but “Series Unknown” appears in 4 of 7 entries (Tali Resources, Stavely Minerals, OncoRes Medical, Argenica Therapeutics), with disclosed amounts ranging from $840K (Argenica Therapeutics, 2023-01-20) up to $19M.
Most recent rounds
7 shownRelated listings
Frequently asked
What’s the largest disclosed round in the Nedlands list, and how does it compare to the others?
OncoRes Medical’s $19M on 2026-02-12 is the largest disclosed amount in these 7 rows. It sits well above the next-highest disclosed amounts at $11M (BARD1 Life Sciences, 2021-07-23) and $4M (My Mirror, 2024-12-01).
Are there time clusters among the most recent rounds for Nedlands?
Yes. 3 of the 7 rounds are in 2026, all concentrated between 2026-02-12 and 2026-05-07 (OncoRes Medical $19M; Stavely Minerals $3M; Tali Resources $2M). Outside that window, My Mirror’s 2024-12-01 $4M stands apart from the earlier biotech set in 2021–2023.
Which sectors are over-represented in these 7 entries?
Biotechnology is the clear concentration, appearing in 4 of 7 rows: OncoRes Medical ($19M, 2026-02-12), Lixa ($2M, 2022-09-06), Argenica Therapeutics ($840K, 2023-01-20), and BARD1 Life Sciences ($11M, 2021-07-23). The remaining sectors are Natural Resources (Tali Resources), Financial Services (Stavely Minerals), and Health Care (My Mirror).
How complete is stage information, based on the listing’s stage labels?
Stage is labeled “Series Unknown” in 4 of 7 rows (Tali Resources 2026-05-07 $2M; Stavely Minerals 2026-04-29 $3M; OncoRes Medical 2026-02-12 $19M; Argenica Therapeutics 2023-01-20 $840K). The other labeled stages are Seed (My Mirror, 2024-12-01 $4M), Series A (Lixa, 2022-09-06 $2M), and Post-IPO Equity (BARD1 Life Sciences, 2021-07-23 $11M).
Is there a meaningful outlier in the disclosed amounts?
Yes: OncoRes Medical at $19M on 2026-02-12 is the high outlier. The smallest disclosed amount is Argenica Therapeutics at $840K on 2023-01-20, and the next-largest figures below the top are $11M (BARD1 Life Sciences, 2021-07-23) and $4M (My Mirror, 2024-12-01).
Which entries fall closest to the most recent round date shown?
Using the latest date in the rows (2026-05-07 for Tali Resources $2M), the entries within the following ~90 days are Tali Resources (2026-05-07 $2M), Stavely Minerals (2026-04-29 $3M), and OncoRes Medical (2026-02-12 $19M). The remaining entries are dated 2024-12-01 and earlier.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.